GlaxoSmithKline plc
Pharmaceuticals & BiotechnologyFounded 1715- Updated June 2026
Reviewed by Swet Parvadiya
Last reviewed: June 2026
CorpDigest
GlaxoSmithKline plc
Company History
Founded 1715 in London, United Kingdom
Last reviewed: 2026-06-09 · By Swet Parvadiya
GlaxoSmithKline plc commands a $102.3 billion market capitalization as of June 2026, generating $40.1 billion in FY2024 revenue through a highly concentrated portfolio of virology and immunology assets, with the HIV franchise contributing $7.2 billion and the vaccines division adding $9.1 billion. The company's financial architecture is defined by a 79 percent gross margin, driven by the operating leverage of its Specialty Medicines division, which accounts for 54 percent of total sales and benefits from high per-unit pricing and specialized distribution channels. Under the leadership of CEO Luke Miels, who assumed the role on January 1, 2026, GSK has executed a ruthless pivot toward high-margin, scientifically complex therapeutics, eliminating the $13 billion consumer healthcare joint venture and redirecting capital toward late-stage oncology and antibody-drug conjugate pipeline assets. This strategic transformation has allowed the company to maintain a free cash flow yield of 6.8 percent, funding a $3.5 billion annual dividend and a $7.2 billion R&D budget focused on the long-acting respiratory biologic Exdensur and the myeloma ADC GSK-572. Despite facing acute regulatory volatility, evidenced by the 74 percent Q3 2024 sales collapse for Arexvy following US CDC guidance changes, and the impending patent expiration for Triumeq in 2027, GSK maintains a dominant market position in the recombinant protein vaccine space through its proprietary AS01 adjuvant platform, a technological moat that competitors cannot replicate due to the agricultural bottleneck in the QS-21 supply chain. The company's ability to navigate the complex regulatory environments of the US, Europe, and China, while simultaneously managing the patent cliffs of its legacy franchises, will determine whether this three-century-old institution can maintain its position as a top-tier global pharmaceutical leader.
Silvanus Bevan was an 18th-century apothecary who founded the Plough Court Pharmacy in London in 1715, the earliest ancestral entity of what would eventually become GlaxoSmithKline. Operating during a period when the pharmaceutical profession was largely unregulated and dominated by quackery, Bevan distinguished himself by adhering to strict compounding standards and sourcing the highest quality raw materials for his herbal remedies and tinctures. His pharmacy became a trusted resource for the local population and the emerging medical community, establishing a reputation for quality and integrity that would be carried forward by subsequent generations of owners. Bevan's decision to focus on scientific rigor rather than quick profits set the foundational culture for the enterprise, a culture that would survive the Industrial Revolution, the Great Plague, and the modern biotechnology revolution. The Plough Court Pharmacy was subsequently acquired by Allen & Hanburys in 1873, which transformed it into a major pharmaceutical manufacturer, but the core values established by Bevan in 1715 remained central to the company's identity. His legacy is not one of specific scientific discoveries, but of the institutional commitment to quality and ethical business practices that has allowed the entity to survive and thrive for over three centuries.
Joseph Nathan was a New Zealand-based merchant who established the Glaxo brand in 1892, creating the entity that would eventually merge with Wellcome to form Glaxo Laboratories. Initially, the company focused on importing and distributing powdered milk products, a decision driven by the high demand for infant nutrition in the colonial markets of the Pacific. Nathan's choice of the brand name 'Glaxo,' derived from the Latin word 'glacies' meaning ice, was a strategic branding decision that emphasized the purity and preservation qualities of the product, a marketing message that resonated strongly with consumers concerned about food safety. The Glaxo brand became highly successful in the Australasian market, allowing Nathan to expand the business into the United Kingdom in the early 20th century. The company's transition from nutrition to pharmaceuticals began in the 1930s when it acquired the dairy company Greensborough and subsequently began manufacturing vitamin D supplements, a natural extension of its expertise in nutritional science. This strategic pivot laid the groundwork for the company's eventual merger with Allen & Hanburys in 1958 and its subsequent evolution into a major pharmaceutical player. Nathan's legacy is the creation of a powerful brand identity that emphasized purity and scientific quality, a brand that would become synonymous with pharmaceutical excellence in the UK and beyond.
Silas M. Smith was an American entrepreneur who opened a herbal medicine shop in New York in 1830, establishing the earliest ancestral entity of what would become SmithKline Beecham. Operating during a period of rapid industrialization and westward expansion in the United States, Smith recognized the growing demand for standardized, mass-produced medicinal products. His decision to partner with his nephew Mahlon Kline in 1871 was a pivotal moment in the company's history, as Kline brought formal pharmaceutical training and a focus on scientific manufacturing processes that transformed the business from a simple retail operation into a major pharmaceutical manufacturer. The newly formed Smith, Kline & French quickly gained a reputation for quality and innovation, introducing the first mass-produced amphetamine inhaler in 1930 and the blockbuster antidepressant Paxil in 1992. The company's American lineage was characterized by a strong commercial focus and a willingness to invest in new technologies, a culture that would eventually clash with the more research-oriented culture of the British Glaxo Wellcome when the two companies merged in 2000. Smith's legacy is the creation of a commercially driven pharmaceutical enterprise that would become one of the largest and most successful drug manufacturers in the United States, setting the stage for the monumental 2000 merger that created the modern GlaxoSmithKline.
Silvanus Bevan opens a small pharmacy at Plough Court in London, establishing the earliest ancestral entity of GlaxoSmithKline, which would accumulate over three centuries of continuous operational history.
Joseph Nathan establishes the Glaxo brand in New Zealand, initially focusing on powdered milk products, a decision that would later provide the foundation for the company's transition into pharmaceutical manufacturing.
Silas M. Smith's herbal medicine shop is joined by his nephew Mahlon Kline to form Smith, Kline & French, introducing the first mass-produced amphetamine inhaler and establishing a major American pharmaceutical manufacturer.
Glaxo Laboratories acquires the pharmaceutical company Allen & Hanburys, which had previously acquired the Plough Court Pharmacy, creating a major British pharmaceutical entity with a strong respiratory franchise.
Glaxo Laboratories merges with the Wellcome Foundation to form Glaxo Wellcome, creating a $15 billion pharmaceutical powerhouse with a dominant position in the anti-ulcer and antiviral markets.
Glaxo Wellcome and SmithKline Beecham merge in a $76 billion transaction, creating the world's largest pharmaceutical company by market capitalization with $24 billion in annual revenue and 100,000 employees.
GSK forms a consumer healthcare joint venture with Novartis, acquiring the rights to brands like Sensodyne and Panadol in a $13 billion transaction that would later be reversed with the 2022 demerger of Haleon.
The FDA approves Shingrix, the recombinant zoster vaccine that utilizes the proprietary AS01 adjuvant platform to achieve a 97.2 percent efficacy rate, capturing 82 percent of the global shingles market and generating $4.2 billion in annual revenue.
GSK completes the demerger of its consumer healthcare division into the independent entity Haleon plc, a transaction valued at approximately $39 billion that eliminated the conglomerate discount and redirected capital toward high-margin specialty medicines.
The FDA approves Arexvy, the first RSV vaccine for adults over 60, which generated $1.9 billion in sales before suffering a catastrophic 74 percent year-over-year sales decline in Q3 2024 following US CDC ACIP guidance changes.
Luke Miels assumes the role of CEO on January 1, 2026, following the departure of Emma Walmsley, marking a decisive shift toward a ruthless, product-centric strategy that prioritizes late-stage clinical assets in oncology and immunology.
GSK anticipates the launch of the long-acting respiratory biologic Exdensur, a bispecific antibody that targets both IL-4 and IL-13, positioned to capture 22 percent of the $28 billion COPD market by 2030.
GSK acquired Sierra Oncology to secure rights to a novel myeloid malignancy drug platform, specifically the antibody-drug conjugate GSK-572, which targets the BCMA antigen in multiple myeloma and is currently in Phase 3 clinical trials.
GSK acquired IDRx, a developer of novel tyrosine kinase inhibitors that overcome resistance mutations in non-small cell lung cancer, to complement the ADC pipeline and provide a comprehensive oncology portfolio that can compete with the offerings of Novartis and Roche.
GSK acquired Pulmocide to secure rights to a proprietary lipid nanoparticle delivery system for inhaled gene therapies, a critical technology for the development of the cystic fibrosis treatment PM-101, which is currently in Phase 2 clinical trials.